[ad_1]
The WHO stated that severely ill Covid patients who cannot produce an adequate immune response can receive synthetic antibody therapy Regeneron
The World Health Organization (WHO) recommended a synthetic antibody against Covid-19 to treat Regeneron on Friday, but only for patients with specific health conditions.
According to the findings of a survey published by the World Health Organization on the BMJ, people with non-serious Covid-19 but still at high risk of hospitalization can take the antibody combination, and severely ill patients who cannot produce an adequate immune response can also take this antibody combination.
Regeneron is just the third Covid treatment recommended by the global health authorities and added it to their “WHO current guidelines” on Covid-19 drugs.
In July, the WHO approved a class of drugs that suppress the immune system’s dangerous overreaction to the SARS-CoV-2 virus that causes Covid.
These drugs work well with corticosteroids, which were first recommended by the WHO for Covid patients in September 2020.
According to the BMJ, according to three clinical trials that have not been peer-reviewed, it has been found that a Regeneron cocktail composed of synthetic antibodies (casirivimab and imdevimab) can reduce the risk of hospitalization for unvaccinated, elderly or immunosuppressed Covid patients.
For the second category of patients covered by the new WHO recommendations, another trial reported that the number of deaths of patients taking these drugs and the number of cases requiring mechanical ventilation have decreased.
“For all other covid-19 patients, any benefit of this antibody therapy is unlikely to be meaningful,” WHO concluded.
Designed by the biotechnology company Regeneron and marketed by the pharmaceutical giant Roche under the name Ronapreve, this treatment was given during the period when former US President Donald Trump was infected with the coronavirus.
When used together, the monoclonal antibodies cassireimab and imdevimab bind to the SARS-CoV-2 spike protein to neutralize the ability of the virus to infect cells.
The World Health Organization “welcomes the addition of another treatment method to the global arsenal of COVID-19”, but expressed concern about the impact of high prices on health inequality.
“Given the high cost and low availability of combination therapies, [global health agency] UNITAID is negotiating with Roche Pharmaceuticals… to reduce prices and distribute them fairly in all regions, especially in low- and middle-income countries,” the WHO said in a separate statement.
“WHO is still discussing with the company to donate and distribute this medicine through UNICEF.”
The United Nations health authorities also called on other manufacturers to submit “biosimilar” versions of the drug for approval.
In July, Japan became the first country to fully approve the Regeneron antibody to treat patients with mild to moderate Covid-19.
The antibody combination has been authorized for emergency or temporary pandemic use in many countries and regions, including the European Union, the United States, India, Switzerland and Canada.
[ad_2]
Source link